The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The Food and Drug Administration announced it has approved nivolumab, or Opdivo, marketed by Bristol Myers (BMY) Squibb, with ipilimumab, or ...

The FDA has approved the use of nivolumab (Opdivo) with ipilimumab (Yervoy) in adult and pediatric patients age 12 or older ...

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient (dMMR), surgically resectable endometrial cancer, according to findings presented at the SGO 2025 Annual ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nivolumab plus ipilimumab or relatlimab nearly doubled response rates compared to nivolumab alone in head and neck cancer.

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Hedyeh Ebrahimi, MD, MPH, discusses updated data from a phase 1 study of CBM588, cabozantinib, and nivolumab in metastatic renal cell carcinoma.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.